U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 2, 2010
SUNSHINE BIOPHARMA, INC.
(Exact name of small business issuer as specified in its charter)
|
Colorado
|
000-0-52898
|
20-5566275
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer ID No.)
|
6100 Royalmount Ave.
Montreal, Quebec, Canada H4P 2R2
(Address of principal executive offices)
(514) 496-5197
(Issuer's Telephone Number)
Item 3.02 Unregistered Sale of Equity Securities and Use of Proceeds
Effective June 2, 2010, we authorized the issuance of an aggregate of 1,675,000 shares of our “restricted” Common Stock, to the following entities, in the amount and in consideration for the services indicated:
|
Consultant
|
# of Shares
|
Purpose
|
||
|
The Video Agency, Inc.
|
375,000
|
Advertising
|
||
|
Brockington Securities, Inc.
|
300,000
|
Financial Consulting
|
||
|
Insight Capital Consultants Corporation
|
650,000
|
Financial Consulting
|
||
|
Alchemy Financial Services Inc.
|
300,000
|
Public Relations
|
||
|
CJR Capital Advisors Inc.
|
50,000
|
Financial Consulting
|
||
|
TOTAL
|
1,675,000
|
We relied upon the exemption from registration provided by Section 4/2 as promulgated under the Securities Act of 1933, as amended, to issue these shares. We did not receive any cash compensation as a result of the issuances of these shares.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: June 2, 2010
|
SUNSHINE BIOPHARMA, INC.
(Registrant)
|
|
By: s/Steve N. Slilaty______________________
Dr. Steve N. Slilaty
Chief Executive Officer
|